Gene Therapy

AAV, lentiviral, and non-viral delivery for therapeutic gene transfer and editing.

frontier tier

Gene Therapy addresses aav, lentiviral, and non-viral delivery for therapeutic gene transfer and editing. As a subfield of stem cell and regenerative biology, it sits within the broader biology branch of the Charted science tree and connects upward to the methodological themes of its parent area.

A more detailed frontier sourcing pass for this topic is deferred to a follow-up OpenAlex wave; the current sources include Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (Maude et al., 2018), each kept as a placeholder anchor for the next iteration. See the parent topic (biology/stem-cell-and-regenerative-biology) for the wider context this page will eventually slot into.

Prerequisites

Sources

In context

Where this topic sits in the prerequisite graph. Click any node to jump.

Open in full atlas →

Explore

  1. 01

    Lipid Nanoparticle Delivery

    LNP formulations for in vivo delivery of nucleic acids and gene-editing payloads.

Review this topic

This page was drafted by an agent and is waiting on expert review. Spotted a wrong prerequisite, a missing concept, a misattributed source, or a factual slip? Tell us — your review opens a tracked issue maintainers act on.